Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM
Generex Biotechnology Corporation (OTCQB:GNBT) announced details for a shareholder conference call on May 6, 2021. The call aims to address the surge in participant interest and improve access for shareholders. Pre-registration is encouraged through a provided link to facilitate attendance. President & CEO Joseph Moscato will update shareholders on key developments, including progress on the Ii-Key-SARS-CoV-2 Complete Vaccine™ and expansion of Arizona operations. The company emphasizes its commitment to enhancing shareholder engagement and communication.
- Increased shareholder engagement with improved conference call access.
- Updates on the Ii-Key-SARS-CoV-2 Complete Vaccine™ progress.
- Expansion plans for Arizona operations.
- None.
MIRAMAR, Fla., May 04, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced the call in details and an updated agenda for the shareholder conference call on Thursday May 6, 2021 at 9:00 AM.
Due to a significant rise in the number of participants during recent calls, we are adding new conference call options. This will allow for easier call-in access for all callers & correct the question & answer issues that occurred during our last call.
You are now able to pre-register for the conference call by using the Direct RSVP link below. You will receive, via email, a personal Conference Pin Code allowing you to check yourself into the Conference Call. The Direct RSVP link will be available up until one hour before the call.
Participants may send pre-conference call questions to info@generex.com. Questions will be reviewed by President & CEO Joseph Moscato and will be directly answered on the call, or during the corporate presentation.
Additionally, callers can also join the Conference Call the same way you have in the past by dialing in & listening to the presentation and Q&A portion. If during the call you would like to ask a question and you have not pre-registered, you will have to provide your personal information to the operator.
We have added these options for you, our shareholders, to make it easier for you to join the call and to have your questions answered. We do suggest all participants pre-register for the call by using the DirectRSVP link option for best results.
Direct RSVP Link: https://directrsvp.com/DirectRSVP/WebForms/EventRegistration.aspx?InvCode=8096a214-a4c4-41f5-b42e-2b069ba75d1b
Call in Information:
Toll Free: 1-866-342-8588
Local Call: 1-203-518 9865
Conference ID: 52744
Mr. Moscato said, “I look forward to Thursday morning’s call to give our shareholders an update of all corporate activities. Including an Ii-Key-SARS-CoV-2 Complete Vaccine™ progress report, the build out and launch of our Arizona operations and the recent developments with our Olaregen Excellegan products.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. Please visit our newly designed website: https://www.generex.com
About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program. For more information, please visit: https://www.nugenerexio.com
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
investor@generex.com
FAQ
What is the date and time of Generex's shareholder conference call?
How can shareholders participate in the Generex conference call?
What key updates will be provided during the Generex call?
What company issued the press release?
